Global Blood Screening Market by Product (Reagent, Instrument), by Technology (CLIA & EIA, NAT, Western Blotting, NGS, ELISA) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global blood screening market was worth USD 1.6 billion in 2015. It is expected to grow at 10.2% CAGR over the forecast period. Blood screening involves the testing of donated blood for certain infectious diseases like HBV, HCV and HIV1. This market has seen a high growth rate due to increasing blood donations, increased incidence of infectious diseases and government initiatives.

Various governments and organizations have taken initiatives to increase awareness of donation and screening prior to transfusion. The WHO estimates that approximately 108 million blood donors are collected each year around the world. Half of these blood donations are from countries with high incomes, which account for less than 20% the world's population. The rising demand for safe blood and increased awareness creates opportunities in emerging nations.

In 2010, almost all countries had a 100% screening rate for HIV, hepatitis B and hepatitis C viruses. The WHO set a 2020 goal for safe blood access in order to motivate volunteers. These initiatives encourage voluntary donations and will likely propel the market over the forecast period.

Australia Red Cross launched two initiatives to increase voluntary donation on the 14th June 2016. This day is world blood donor day. The first is an SMS alert, and the second is a toolkit which reduces anxiety and increases voluntary donation in Australia.

Product Insights

Reagent was the dominant agent in 2015, and it is expected to continue its dominance during the forecast period. The market would benefit from greater accuracy and precision in detecting the presence and type of different elements in small samples.

Reagents are also cost-effective and provide a high return of investment for vendors. The market for blood screening instruments is expected to grow in 2016-2024 due to their high cost and reuseability.

Instrument held a significant market share due to the introduction of new devices into the market following their approval. In October 2017, FDA approved Roche's Cobas Zika Donor Screening Test for Zika virus. This will stop Zika virus spreading to the United States through blood donation.

Technology Insights

The sensitivity and specificity of the nucleic acids amplification test (NAT), which is sensitive to viral nucleic acids, will allow it to grow at a faster rate. This test detects nucleic acids earlier than other screening methods, which reduces the time window for HBV, HCV and HIV infections.

NAT was first introduced in developed countries in the 1990s and 2000. NAT was implemented in 33 countries worldwide for HIV/AIDS, and 27 for hepatitis B virus. The methods that fall under this segment are polymerase chain reaction, ligase chain reaction, and transcription-mediated amplification.

Roche was approved by the U.S.FDA in October 2016 for the next generation of cobas MPX donor screening tests to prevent the spread virus through blood transfusion. Cobas MPX is a NAT that detects five viruses HIV-1 group O, HIV-1 group M, HIV-2, HIV-2, HBV and HCV from one sample.

The second largest market share was held by ELISA. This technology's growth is due to its constant development to improve its specificity and low cost compared to NAT. It also has the benefit of increasing the prevalence of infectious diseases within Asia Pacific. There are many ELISA types on the market.

Regional Insights

North America was the country with the highest revenue share in 2015. Its position in the future is due to key industry players, greater adoption of blood screening, strict FDA regulations for transfusion and greater affordability for patients.

Vela Diagnostics was awarded CE for its PC-based Sentosa SA ZIKVPCR Test. A blood screening test for Zikacan detects Zika virus infection in a recipient. Roche also launched a next-generation viral load test in March 2015 to detect HBV in Europe. It is a COBAS-HBV quantitative nucleic acids test for COBAS 6800/8800 systems. The region's adoption and launch of these new technologies is likely to boost the European industry.

Asia Pacific is the fastest-growing region. This is due to rising awareness about blood donation, rising affordability of patients, and a growing focus by key industry players on emerging nations in the region. The Asia Pacific region is home to major contributors such as Australia, Japan, India and China.

Market Share in Blood Screening

Becton Dickinson and Company, Thermo Fisher Scientific., Ortho-Clinical Diagnostics, Inc., Grifols, Danaher Corporation(Beckman Coulter), Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., and Siemens AG are some of the major players in this industry.

Companies use two key strategies to gain market share: partnership or collaborations and the development of new products. Grifols was awarded CE for its Procleix HEV test, which uses NAT in order to detect the hepatitis Evirus. Hologic, Inc. developed the test. Collaboration for commercialization is expected to drive the industry in the forecast period.

Blood Screening Market Report Scope

The report covers segments

This report provides industry trends analysis and forecasts for revenue growth from 2013-2024. Grand View Research has divided the global blood screening market report by technology, region, and product.

• Blood Screening Technology Outlook (Revenue USD Million; 2013-2024)

  • Nucleic Acid Amplification Test (NAT)

  • ELISA

  • Enzyme Immunoassay and Chemiluminescence Immunoassay are available (EIA).

  • Next-Generation Sequencing (NGS)

  • Western Blotting

• The Blood Screening Product Outlook (Revenue USD Million; 2013-2024)

  • Reagent

  • Instrument

• Blood Screening Regional Outlook (Revenue USD Million; 2013-2024)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa

These are the most frequently asked questions about this report

b. Global blood screening market size was USD 2.4 billion in 2019, and is forecast to rise to USD 2.7 billion by 2020.

b. Global blood screening market to reach USD 3.9 billion in 2024 is projected to grow at 10.2% compound annual growth rate from 2016 to 2024.

b. With a market share of 45.4%, North America dominated blood screening in 2019, This can be attributed to the presence and affordability of patients, strict FDA regulations regarding transfusions, and increased adoption of blood screening processes.

b. Becton Dickinson and Company, Thermo Fisher Scientific., Ortho-Clinical Diagnostics, Inc., Grifols, Danaher Corporation(Beckman Coulter), Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., and Siemens Healthineers are some of the key players in the blood screening market.

b. Market growth is driven by rising blood donation, an increase in the incidence and government initiatives.

Up Market Research published a new report titled “Blood Screening Market research report which is segmented by Product (Reagent, Instrument), by Technology (CLIA & EIA, NAT, Western Blotting, NGS, ELISA), By Players/Companies Inc, Danaher Corporation (Beckman Coulter), F Hoffmann-La Roche Ltd; and Siemens Healthineers, Grifols, Abbott Laboratories; Bio-Rad Laboratories, Ortho-Clinical Diagnostics, Becton Dickinson and Company, Thermo Fisher Scientific, Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Blood Screening Market Report Segments:

The market is segmented by Product (Reagent, Instrument), by Technology (CLIA & EIA, NAT, Western Blotting, NGS, ELISA).

Blood Screening Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Blood Screening Market

Overview of the regional outlook of the Blood Screening Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Blood Screening Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Blood Screening Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Reagent

                2. Instrument

                1. CLIA & EIA

                2. NAT

                3. Western Blotting

                4. NGS

                5. ELISA

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Blood Screening Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Blood Screening Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.